Dr. Steve Nissen on 3 ESC 2017 Trials That Really Matter (Video)

Beyond the headlines on CANTOS, REVEAL, COMPASS

If you didn’t make it to the European Society of Cardiology (ESC) Congress 2017 the other week, Cleveland Clinic’s Steven Nissen, MD, has got you covered. In the five-minute video below, Dr. Nissen recaps and interprets three important late-breaking trials presented at the meeting:

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

  • The CANTOS trial of the monoclonal antibody canakinumab and why it represents a turning point in approaches to coronary artery disease
  • The REVEAL trial of the CETP inhibitor anacetrapib and why this agent is unlikely to gain FDA approval despite meeting the study’s primary end point
  • The COMPASS trial and why there’s a price to be paid for giving an antiplatelet drug with an anticoagulant drug in chronic coronary disease

As Dr. Nissen puts it in the video: “Three trials, three different domains, three pretty interesting results.”